Cargando…

Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Detalles Bibliográficos
Autores principales:	Medisetty, Mahender Kumar, Patel, Atul, Pujari, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883703/ https://www.ncbi.nlm.nih.gov/pubmed/33601033 http://dx.doi.org/10.1016/j.ijid.2021.02.035

Ejemplares similares

Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
por: Udwadia, Zarir F., et al.
Publicado: (2021)

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
por: Udwadia, Zarir F., et al.
Publicado: (2021)

Dr. Tehemton E. Udwadia: A tribute and eulogy
por: Bhandarkar, Deepraj S., et al.
Publicado: (2023)

AIDS Cholangiopathy Secondary to Cytomegalovirus as Possible Unmasking Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Individual: Case Report and Review of the Literature
por: Topiwala, Moiz, et al.
Publicado: (2018)

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
por: FURUTA, Yousuke, et al.
Publicado: (2017)

Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP
por: Naydenova, Katerina, et al.
Publicado: (2021)

Model of the RNA Polymerase Complex of the SARS-CoV-2 Virus with Favipiravir
por: Polyakov, I. V., et al.
Publicado: (2021)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase
por: Shannon, A., et al.
Publicado: (2020)

Effects of the RNA-Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers—An MD Study
por: Bringas, Mauro, et al.
Publicado: (2022)

Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India
por: Joshi, Shashank, et al.
Publicado: (2022)

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial
por: Bosaeed, Mohammad, et al.
Publicado: (2021)

Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial
por: Zhao, Hong, et al.
Publicado: (2021)

Efficacy of Favipiravir in treatment of mild & moderate COVID-19 infection in Nepal: a multi-center, randomized, open-labelled, phase III clinical trial
por: Adhikari, P., et al.
Publicado: (2022)

Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
por: AlQahtani, Manaf, et al.
Publicado: (2022)

High Prevalence of Cryptococcal Antigenaemia and Disseminated Cryptococcal Disease Amongst Patients with Advanced HIV Disease in Pune, India
por: Kumar Medisetty, Mahender, et al.
Publicado: (2017)

An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand
por: Sarojvisut, Phahol, et al.
Publicado: (2023)

PIONEER trial: favipiravir to treat moderate COVID-19
por: Shalhoub, Sarah
Publicado: (2023)

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis
por: Shannon, Ashleigh, et al.
Publicado: (2020)

Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir
por: Peng, Qi, et al.
Publicado: (2021)

Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial
por: Chen, Chang, et al.
Publicado: (2021)

Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
por: Reddy, Pavan Kumar, et al.
Publicado: (2022)

Author Correction: Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
por: AlQahtani, Manaf, et al.
Publicado: (2022)

Response to the Letter to the Editor
por: Majeed, Chaudry Nasir, et al.
Publicado: (2020)

In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase
por: Celik, Ismail, et al.
Publicado: (2021)

Live cell immunogold labelling of RNA polymerase II
por: Orlov, Igor, et al.
Publicado: (2015)

Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia
por: Al-Muhsen, Saleh, et al.
Publicado: (2022)

Letter to the Editor [Letter]
por: Félix, Sylvie
Publicado: (2021)

Letter to the editor: Does Dicer Expression Affect shRNA processing?
por: Senzer, Neil, et al.
Publicado: (2009)

Detailed Analyses of Molecular Interactions between Favipiravir and RNA Viruses In Silico
por: Shirai, Tatsuya, et al.
Publicado: (2022)

Letter to Editor regarding “Unusual Presentation of Spontaneous Chylothorax”
por: Varghese, Anjali Rachel, et al.
Publicado: (2022)

Real-Time Polymerase Chain Reaction Assay: A Response to Recent Letter to the Editor
por: Kim, Seo Woo, et al.
Publicado: (2016)

Selective RNA Labeling by RNA-Compatible Type II Restriction Endonuclease and RNA-Extending DNA Polymerase
por: Jo, Hyesung, et al.
Publicado: (2022)

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study()
por: Cai, Qingxian, et al.
Publicado: (2020)

Favipiravir/voriconazole: Hyperuricaemia, transaminitis and off-label use: case report
Publicado: (2021)

Azithromycin/favipiravir/hydroxychloroquine: Hypoglycaemia and off label use: case report
Publicado: (2021)

Favipiravir: Liver injury following an off-label use: case report
Publicado: (2021)

Favipiravir: Acute pancreatitis following an off-label use: case report
Publicado: (2021)

Favipiravir: Lack of efficacy following off-label treatment: case report
Publicado: (2021)

Antineoplastics/ciclesonide/favipiravir: Pancytopenia and off-label use: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b18jlj4ua30a2fl38hnj6hojk0